LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
1,82 $
0,00%
(0,00) 1 d.
1,81 $
arrow_downward
-0,68% (-0,012)bedtimePēctirdzniecības
Slēgts: 2. okt., 16:00:01 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: LXRX…
Atvērt
1,85 $
Augsta
1,87 $
Zema
1,80 $
Tirgus kapitalizācija
809,82 milj.
Vid. apjoms
3,13 milj.
Apjoms
2,32 milj.
Augstākā 52 ned.
2,68 $
Zemākā 52 ned.
1,10 $
Peļņa uz vienu akciju
-0,15 $
Beta
1,36
Apgrozībā esošās akcijas
444,96 milj.
Darbinieku skaits
81
Atvērt
1,85 $
Augsta
1,87 $
Zema
1,80 $
Tirgus kapitalizācija
809,82 milj.
Vid. apjoms
3,13 milj.
Apjoms
2,32 milj.
Augstākā 52 ned.
2,68 $
Zemākā 52 ned.
1,10 $
Peļņa uz vienu akciju
-0,15 $
Beta
1,36
Apgrozībā esošās akcijas
444,96 milj.
Darbinieku skaits
81
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Seeking Alpha
·
pirms 2 dienām
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Profils
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
Par “Lexicon Pharmaceuticals Inc”
ĢenerāldirektorsLonnel Coats
Darbinieki81
Dibināšanas datums1995
Galvenais birojs-
Sektors-
Tīmekļa vietnelexpharma.com